Open AccessResponse to pegylated interferon in a COVID‐19–positive elderly woman with primary myelofibrosis treated with ruxolitinib
Author(s) -
Frankel Arthur E.,
Reddy Renuka,
DeSuza Kayla R.,
Deeb Khaled,
Carlin Aaron F.,
Smith Davey,
Xie Yushuang,
Naik Eknath,
Silver Richard T.,
Hasselbalch Hans C.
Publication year - 2021
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.3997
Subject(s) - ruxolitinib , medicine , asymptomatic , myelofibrosis , pegylated interferon , covid-19 , interferon , virology , ribavirin , immunology , gastroenterology , virus , bone marrow , hepatitis c virus , disease , infectious disease (medical specialty)
An 83‐year‐old female had asymptomatic SARS‐CoV‐2 infection while taking ruxolitinib. She remained RT‐PCR positive for viral RNA for >120 days, and Pegylated interferon for 4 weeks led to viral RNA clearance. The observations support combination therapy of ruxolitinib + interferon for COVID‐19.